Fondaparinux sodium

Drug Profile

Fondaparinux sodium

Alternative Names: Arixtra; GSK 576428; ORG 31540; Quixidar; SR 90107; SR 90107A; Xantidar

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer GlaxoSmithKline
  • Class Anticoagulants; Antithrombotics; Polysaccharides
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Deep vein thrombosis; Myocardial infarction; Pulmonary embolism; Thromboembolism; Unstable angina pectoris; Venous thrombosis

Most Recent Events

  • 12 Sep 2016 Aspen acquires rights for fondaparinux sodium in China, India and Pakistan from GlaxoSmithKline
  • 15 Mar 2016 Biomarkers information updated
  • 31 Dec 2014 Fondaparinux sodium licensed to Mylan in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top